BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Argus Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,268,489

« Back to Dashboard

Which drugs does patent 6,268,489 protect, and when does it expire?

Patent 6,268,489 protects ZMAX and ZITHROMAX and is included in seven NDAs. There has been one Paragraph IV challenge on Zithromax.

This patent has sixty-eight patent family members in forty-two countries.

Summary for Patent: 6,268,489

Title: Azithromycin dihydrate
Abstract:Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.
Inventor(s): Allen; Douglas J. M. (New London, CT), Nepveux; Kevin M. (Old Saybrook, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:07/994,040
Patent Claim Types:
see list of patent claims
Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism CvZMAXazithromycinFOR SUSPENSION, EXTENDED RELEASE;ORAL050797-001Jun 10, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinFOR SUSPENSION;ORAL050693-001Sep 28, 1994RXYesYes► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinFOR SUSPENSION;ORAL050710-001Oct 19, 1995ABRXYesNo► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinFOR SUSPENSION;ORAL050710-002Oct 19, 1995ABRXYesYes► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinINJECTABLE;INJECTION050733-001Jan 30, 1997APRXYesYes► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinTABLET;ORAL050711-001Jul 18, 1996ABRXYesNo► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinTABLET;ORAL050784-001May 24, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
PfizerZITHROMAXazithromycinTABLET;ORAL050730-001Jun 12, 1996ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,268,489

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/US87/01612Jul 09, 1987

International Patent Family for Patent: 6,268,489

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ireland882108► Subscribe
Czechoslovakia272241► Subscribe
Cyprus1776► Subscribe
German Democratic Republic271705► Subscribe
Germany3867563► Subscribe
Germany3868296► Subscribe
Denmark380688► Subscribe
Denmark172573► Subscribe
Denmark381188► Subscribe
Egypt18527► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: